The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a $153 million contract to Cellerant Therapeutics, Inc. of San Carlos, Calif., to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation which can damage the body's cells - the type of radiation that would come from a nuclear blast. Under the contract, the company will continue development of a medication called CLT-008 that uses a special kind of cells called myeloid progenitor cells...
More...
More...